- CX516
-
- $29.00 / 10mg
-
2025-04-27
- CAS:154235-83-3
- Min. Order:
- Purity: 99.82%
- Supply Ability: 10g
- Ampalex
-
- $15.00 / 1KG
-
2021-07-13
- CAS:154235-83-3
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- Ampalex
-
- $15.00 / 1KG
-
2021-07-10
- CAS:154235-83-3
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | Ampalex Basic information |
| | Ampalex Chemical Properties |
| Melting point | 88-90°C | | Boiling point | 433.1±25.0 °C(Predicted) | | density | 1.236±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | Chloroform, Methanol | | pka | -0.14±0.30(Predicted) | | form | powder | | color | white to light brown | | Water Solubility | H2O: 5mg/mL, clear |
| | Ampalex Usage And Synthesis |
| Chemical Properties | Tan Solid | | Uses | Ampalex is a AMPA modulator that may exhibit therapeutic properties for treating Alzheimer''s disease, schizophrenia, and mild cognitive impairment (MCI) (1,2,3,4). | | Uses | It is one of a series of AMPA modulators | | Definition | ChEBI: CX-516 is a N-acylpiperidine. | | Biochem/physiol Actions | CX516 is a positive allosteric modulator at AMPA receptor that inhibits the deactivation of AMPA receptors. CX-516 is a nootropic and ampakine agent. | | in vivo | The specific extradimensional deficits produced by sub-chronic or early postnatal postnatal phencyclidine treatment were significantly attenuated by CX516 (10, and 20 mg/kg, s.c.)[1]. | Animal Model: | Male Lister Hooded rats (56-63 postnatal day)[1] | | Dosage: | 5, 10, 20, and 40 mg/kg | | Administration: | Subcutaneously | | Result: | Two doses (10 and 20 mg/kg) were highly significant in improving the extradimensional shift deficit induced by either treatment regimes.
Two doses (5 and 40 mg/kg) was ineffective at reversing the extradimensional impairment induced by the sub-chronic postnatal phencyclidine treatment regime. |
|
| | Ampalex Preparation Products And Raw materials |
|